Baker Bros. Advisors ALMS Position
Active4-Fund ConvergenceBaker Bros. Advisors held their position in ALUMIS INC. (ALMS) in Q4 2025, holding $15.3M worth of shares across 1,562,500 shares.
The position was first reported in Q2 2024 and has been tracked across 7 quarterly 13F filings.
ALMS is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ESK-001 in 78 days (Jul 1, 2026), making the timing of Baker Bros.'s position particularly relevant.
Short interest stands at 12.9% of float with 6.9 days to cover, indicating significant bearish positioning against Baker Bros.'s long thesis.
About ALUMIS INC.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
12.9%
6.9 days to cover
Baker Bros. Advisors ALMS Position History
Frequently Asked Questions
Does Baker Bros. Advisors own ALMS?
Yes. As of Q4 2025, Baker Bros. Advisors holds 1,562,500 shares of ALUMIS INC. (ALMS) valued at $15.3M. This data comes from their SEC 13F filing.
How many hedge funds own ALMS?
4 specialist biotech hedge funds currently hold ALMS, including Cormorant Asset Management, OrbiMed Advisors, Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy ALMS?
Baker Bros. Advisors's position in ALMS was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's ALMS position increasing or decreasing?
Baker Bros. Advisors held their ALMS position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ALMSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →